Aker BioMarine AS provided revenue guidance for the full year of 2023. For the year, The company expects long-term average annual sales growth for Aker BioMarine to be in line with earlier communicated ambitions at around 15%.
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
75 NOK | +0.27% | +2.04% | +63.04% |
Apr. 26 | Aker BioMarine AS Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 26 | Transcript : Aker BioMarine AS, Q1 2024 Earnings Call, Apr 26, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+63.04% | 626M | |
+13.31% | 3.36B | |
-95.58% | 1.61B | |
-2.39% | 1.57B | |
-6.45% | 1.25B | |
-3.69% | 1.24B | |
-.--% | 1.27B | |
0.00% | 1.2B | |
+0.49% | 1.17B | |
-16.35% | 1.16B |
- Stock Market
- Equities
- AKBM Stock
- News Aker BioMarine
- Aker BioMarine AS Provides Revenue Guidance for the Full Year of 2023